Moxifloxacin Accord

Moxifloxacin, the active ingredient in Moxifloxacin Accord, is a fluoroquinolone antibiotic presented as an oral tablet for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and soft‑tissue infections in adult patients. GNH USA supplies Moxifloxacin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin Accord is a fluoroquinolone antibiotic used to manage bacterial infections of the respiratory and skin systems. - Community‑acquired pneumonia: eradicates the causative bacteria and improves clinical outcomes. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating pathogenic organisms. - Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth and relieves symptoms. - Skin and soft‑tissue infections: targets susceptible Gram‑positive and Gram‑negative bacteria to promote healing.

Moxifloxacin Accord may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensation. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: can precipitate cardiac arrhythmias. - Severe allergic reaction: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile infection: colitis due to gut flora disruption. - Hepatotoxicity: significant liver injury in rare cases. - Peripheral neuropathy: persistent numbness or tingling.

Before prescribing Moxifloxacin Accord, clinicians should consider several safety measures. - Assess renal function: dose adjustment may be required in impaired clearance. - Monitor cardiac status: avoid in patients with known QT prolongation or electrolyte disturbances. - Evaluate hypersensitivity: discontinue if signs of allergic reaction appear. - Use cautiously in the elderly: increased risk of tendon injury and CNS effects. - Avoid concomitant use with other QT‑prolonging agents: risk of arrhythmia. - Store at room temperature: keep in the original pack, protect from moisture.

Moxifloxacin Accord can interact with other medicines, necessitating careful review.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of the drug. - Warfarin: may increase anticoagulant effect and bleeding risk. - Systemic corticosteroids: heightened risk of tendon rupture. - Other QT‑prolonging drugs (e.g., quinidine, amiodarone): may cause serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance central nervous system stimulation. - Theophylline: increased plasma concentrations leading to toxicity. - Rifampin: may lower moxifloxacin levels, reducing efficacy.